Back to top
more

Abbott Laboratories (ABT)

(Real Time Quote from BATS)

$106.42 USD

106.42
1,844,364

-0.85 (-0.79%)

Updated Apr 30, 2024 01:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ABT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Abbott Laboratories [ABT]

Reports for Purchase

Showing records 481 - 500 ( 521 total )

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 481

01/24/2011

Company Report

Pages: 7

Trimming Our 2011 Projections to Consensus Levels

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 482

12/31/2010

Company Report

Pages: 10

Price: 24.95

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 483

11/09/2010

Company Report

Pages: 11

Price: 24.95

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 484

10/22/2010

Company Report

Pages: 14

Number of late-stage projects in the Pharma pipeline to boost longer term growth.

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 485

10/21/2010

Company Report

Pages: 9

Sales A Tad Light - High-Quality EPS Beat - Best Gross Margin in At Least a Decade

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 486

10/20/2010

Company Report

Pages: 11

Third Quarter EPS Exceeded Expectations. Sales Were a Little Light.

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 487

10/20/2010

Company Report

Pages: 11

Third Quarter EPS Exceeded Expectations. Sales Were a Little Light

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 488

10/18/2010

Daily Note

Pages: 29

Med Tech September Quarter Preview: Stagnation for Most Large Device Markets

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 75.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 489

09/23/2010

Company Report

Pages: 9

A Very Busy Week -Beetles and Bardoxolone, Integrating Solvay, SPIRIT IV at Two Years and More to ABSORB

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 490

09/17/2010

Company Report

Pages: 14

Likely approval of Bioresorbable stent to further strengthen long term growth prospects.

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 491

09/14/2010

Company Report

Pages: 10

Price: 24.95

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 492

09/12/2010

Company Report

Pages: 7

FDA Panel Meets Wednesday to Decide Fate of Obesity Drug Meridia - Potential for More Negative Headlines, But No Material Damage to ABT Even if Drug Pulled From Market

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 493

08/13/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences.

Provider: WEDBUSH SECURITIES INC.

Analyst: BANK P

Price: 10.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 494

08/02/2010

Company Report

Pages: 10

Price: 24.95

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 495

07/21/2010

Company Report

Pages: 10

The Song Remains the Same

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 496

07/21/2010

Company Report

Pages: 8

This House Is Still Standing Stronger than Ever as Most of the Neighborhood Falls Down Around it - the Big Cap Health Care Product Name to Buy Now

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 497

07/19/2010

Daily Note

Pages: 21

Medical Technology -Med Tech June Quarter Preview: Nothing on the Horizon to Lift the Sector Out of the Doldrums, Although Select Small-Cap Names Should Shine Through

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 75.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 498

07/16/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 499

07/02/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 500

06/04/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party